Communiqué from the Annual General Meeting 2017
At the SpectraCures AGM held in Lund on 23 May 2017, the following decisions were taken. Decisions concerning the adoption of the income statement and balance sheet, etc. The AGM resolved to adopt the income statement and balance sheet for the financial year 2016. The Board of Directors and the Managing director were granted discharge […]
SpectraCure initiates a joint project with German company MedCom GmbH
SpectraCure has initiated a joint project with the German company MedCom GmbH for the improving of SpectraCures technology for the treatment of prostate cancer with photodynamic therapy (PDT). MedCom, based in Darmstadt, is the world leader in image-based control of minimally invasive procedures for diagnostics and treatment. The company delivers technical solutions to several major […]
Patient treatments started in clinical Phase 1 study
The first patient in the SpectraCure Phase 1 study has been treated for prostate cancer at Princess Margaret Cancer Centre in Toronto, Canada. The treatment went well and the patient is doing fine. The SpectraCure IDOSE® Technology for treatment planning and laser light dose delivery to the tumour was used. The treatment method, called Photodynamic […]
Notice of annual general Meeting of SpectraCure AB (publ)
The shareholders of SpectraCure AB (publ), Org.nr 556642-1011 ("the Company") are hereby invited to the annual general meeting on Tuesday 23 May 2017 at. 11.00 at the company's premises, Magistratsvägen 10, 226 43 Lund. Notifications, etc., Shareholders who wish to participate in the annual general meeting must: be entered in the share register maintained by […]
